Adaptimmune Therapeutics has entered into a definitive agreement for the sale of Tecelra, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds. The purchase price is $55 million in cash to be paid upon consummation of the sale, with up to $30 million in potential future payments upon achievement of… Read More
Adaptimmune Therapeutics’ Tecelra (afamitresgene autoleucel) has become the first engineered cell therapy for a solid tumour cancer approved in the US. It is also the first new therapy option in more than a decade for synovial sarcoma, which is a rare, soft tissue cancer that most commonly impacts young adults. Read More
Adaptimmune Therapeutics and Galapagos have entered into a clinical collaboration agreement to develop Adaptimmune’s TCR T-cell therapy for head and neck cancer and other potential solid tumours. Under the terms of the agreement, Adaptimmune will receive an upfront exclusivity payment of $70 million, plus $15 million… Read More
